SNS-401-NG / Sensei Biotherap - LARVOL DELTA

Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights (GlobeNewswire) - "Sensei has initiated IND-enabling studies for SNS-101. Key nonclinical studies include the generation of a broader set of in vivo efficacy data from Sensei’s human VISTA knock-in mouse models, nonclinical pharmacokinetic data, and nonclinical safety data....Sensei intends to initiate IND-enabling studies for...SNS-401-NG...in the second half of 2022."

Preclinical • Oncology

Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights (GlobeNewswire) - "In August, Sensei announced it had selected SNS-101, a potent pH-dependent product candidate that selectively blocks the interaction of VISTA with its receptor, PSGL-1, in the low pH tumor microenvironment; VSIG4 (V-Set and Immunoglobulin Domain Containing 4)...Sensei plans to select a product candidate from this program in 2023; SNS-401-NG...Sensei intends to initiate IND-enabling studies for this product candidate in the second half of 2022."

Clinical • Pipeline update • Oncology • Solid Tumor

Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs - "Sensei Biotherapeutics...announced that it is reprioritizing its pipeline programs to focus on its product candidates, including its multi-antigenic next generation ImmunoPhage candidate, now referred to as SNS-401-NG, and its monoclonal antibody SNS-VISTA (V-set Immunoglobulin Domain Suppressor of T cell Activation) candidate...'We look forward to initiating IND-enabling studies for SNS-VISTA by the end of 2021 and for SNS-401-NG in second half of 2022.'; VSIG4 (V-Set And Immunoglobulin Domain Containing 4) is a potent inhibitor of T cell activity, often overexpressed on macrophages within the tumor microenvironment....anticipates selecting a product candidate from this program in 2023."

New trial • Pipeline update